Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer
D. Tong et al., Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer, CLIN CANC R, 5(6), 1999, pp. 1497-1502
Estrogen receptor (ER), progesterone receptor (PR), the estrogen-inducible
protein pS2, and plasminogen activator inhibitor-1 (PAI-1) are important pr
ognostic factors in primary breast cancer. The protein concentrations of th
ese factors in breast tumors have been well documented, However, few data a
bout the mRNA expression of ER, PR, pS2, and PAI-1 in breast cancer are ava
ilable, which is mostly due to the limitations of conventional techniques f
or mRNA analysis. We have described a competitive reverse transcription-PCR
system for the simultaneous quantification of ER, PR, pS2, and PAI-1 mRNA
in tumor samples. Here, we evaluated 100 tumor biopsies from breast cancer
patients for the mRNA expression of ER, PR, pS2, and PAI-1. The results wer
e analyzed for correlations with protein status and with clinical data. Sig
nificant correlations between mRNA expression levels and protein concentrat
ions of all tested markers were found. In only a few eases was there an obv
ious discordance between the measurable amounts of mRNA and protein, especi
ally for ER and PR. In addition, ER, PR, and pS2 mRNA levels correlated sig
nificantly with each other. No correlation between PAI-1 mRNA amount and th
e expression of the other markers was found. With respect to clinical data,
ER and PR mRNA levels were found to be inversely correlated to tumor size
and histological grade but not to the lymph node status. pS2 and PAI-1 mRNA
expression were not correlated with tumor size, grade, or lymph node invol
vement. In conclusion, competitive reverse transcription-PCR may be used as
an alternative for the study of prognostic factors in human breast cancer
and other malignancies. However, before mRNA expression is measured for dia
gnostics, a presumed concordance of mRNA and protein expression must be eva
luated very carefully for every gene.